Results 191 to 200 of about 10,148,101 (391)

Distribution patterns and evolution of antimicrobial resistance in Gram-negative bacteria within the intensive care unit of a tertiary hospital from 2019 to 2024

open access: yesFrontiers in Microbiology
BackgroundThis study aims to investigate the distribution and drug resistance of Gram-negative bacteria in the intensive care unit (ICU) of a tertiary general hospital in Sichuan Province, with the goal of promoting rational antibiotic use and reducing ...
Xiaoying Chen   +4 more
doaj   +1 more source

Advances in cancer therapy: clinical benefit of new cancer drugs

open access: bronze, 1899
Daniel Tobias Michaeli   +2 more
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression

open access: yesJournal of Immunology Research
Background. This work focused on investigating the role of programmed death ligand 2 (PD-L2) in the progression of breast cancer by utilizing breast cancer specimens and cells. Materials and Methods.
Yuling Sun   +10 more
doaj   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

The Management, Function and Histology of Long Functioning Renal Allografts in Dogs on Immunosuppressive Drug Therapy

open access: green, 1968
A. G. R. Shell   +4 more
openalex   +2 more sources

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy [PDF]

open access: bronze, 1978
Joan M. Bull   +7 more
openalex   +1 more source

Home - About - Disclaimer - Privacy